Other languages Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-22 pm EDT			5-day change	1st Jan Change
0.7101 ^USD	-4.04%		-8.96%	-77.82%

May. 22	Maxim Downgrades Virpax Pharmaceuticals to Hold From Buy	MT
May. 15	Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Virpax Prices Public Offering of Shares, Warrants; Shares Tumble	May. 15
Top Premarket Decliners	May. 15
Investors Await Key Inflation Data for April as US Futures Remain Flat in Wednesday's Premarket	May. 15
Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur	Apr. 30
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research	Feb. 07
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall	Dec. 29
Virpax Pharmaceuticals Announces Leadership Transition	Nov. 17
Virpax Pharmaceuticals, Inc. Announces CEO Changes	Nov. 16
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 16
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review	23-10-31
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit	23-10-02
Novvae Pharmaceuticals Announces Executive Appointments	23-10-02
Altasciences von Virpax ausgewählt, um die Entwicklung eines neuen Medikaments zur Verhinderung der Ausbreitung von grippeähnlichen Viren zu unterstützen	23-09-21
Altasciences choisi par Virpax pour soutenir le développement d'un nouveau médicament pour empêcher la propagation de virus apparentés à la grippe	23-09-21
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals	23-09-18
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method	23-08-10
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate	23-07-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Virpax Pharmaceuticals, Inc.

Equities

VRPX

US9282512063

Other languages

Filters